<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02366871</url>
  </required_header>
  <id_info>
    <org_study_id>15-0187.cc</org_study_id>
    <nct_id>NCT02366871</nct_id>
  </id_info>
  <brief_title>Oral Apixaban (Eliquis) Versus Enoxaparin (Lovenox) for Thromboprophylaxis in Women With Suspected Pelvic Malignancy</brief_title>
  <official_title>The Safety of Oral Apixaban (Eliquis) Versus Subcutaneous Enoxaparin (Lovenox) for Thromboprophylaxis in Women With Suspected Pelvic Malignancy; a Prospective Randomized Open Blinded End-point (PROBE) Design</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Colorado, Denver</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Bristol-Myers Squibb</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Colorado, Denver</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study will evaluate the incidence of major bleeding (including clinically relevant
      non-major (CRNM) bleeding) events in women undergoing surgery for gynecologic cancer with
      apixaban 2.5 mg twice a day (BID) compared to current standard of care, subcutaneous
      enoxaparin 40 mg once a day (QD) for 28 days post surgery.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Apixaban (Eliquis) is an oral anticoagulant for the treatment and prevention of
      thromboembolic events. It is advantageous as there is no need to perform routine blood
      monitoring tests including, international normalized ratio (INR), partial thromboplastin time
      (PTT) and Factor Xa, to determine clotting in participants receiving treatment. Several
      studies have shown the efficacy of apixaban for the treatment and prevention of a venous
      thromboembolism (VTE).

      We anticipate that the same efficacy could be replicated in the prevention of VTE in women
      undergoing surgery for gynecologic cancer. An oral-anticoagulant for standard treatment for
      prevention of VTE outcomes following surgery could help improve the surgical mortalities
      associated with gynecologic oncology surgical patients, improve patient adherence for
      outpatient treatment, and reduce VTE surveillance and outcomes.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">April 28, 2015</start_date>
  <completion_date type="Actual">June 2019</completion_date>
  <primary_completion_date type="Actual">June 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants With Incidence of Major Bleeding</measure>
    <time_frame>Day 1 post-op/standard of care first medication dose to day 90 (+/-14 days) post-op/standard of care</time_frame>
    <description>The International Society on Thrombosis and Hemostasis criteria (ISTH) will be used to assess incidence of major bleeding. Participants were monitored for up to 90 days. This is the number of participants who have had at least one major bleeding incidence during the time of observation.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With Incidence of Clinically Relevant Non Major Bleeding Events</measure>
    <time_frame>Day 1 post-op/standard of care first dose of medication to day 90 (+/- 14 days) post-op/standard of care</time_frame>
    <description>Participants were monitored for up to 90 days. This is the number of participants with bleeding events that did not meet the ISTH criteria but still required intervention. This is the number of participants who had at least one non-major bleeding event during the time of observation.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Incidence of Venous Thromboembolism (VTEs): Deep Vein Thrombosis (DVT) or Pulmonary Embolism (PE)</measure>
    <time_frame>Day 1 post-op/standard of care to day first dose of medication 90 (+/- 14 days) post-op/standard of care</time_frame>
    <description>Participants were monitored for up to 90 days. Both DVTs and PEs will be measured using the Wells criteria, ultrasound, and/or CT. This is the number of participants who had at least one DVT or PE during the time of observation.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Who Met Medication Adherence Rates</measure>
    <time_frame>Day 1 post-op/standard of care first dose of medication to Day 28 (+/- 4 days) post-op/standard of care</time_frame>
    <description>Participants were monitored for up to 28 days. This was measured through self-report, patient diaries, and the return of all medication bottles/syringes. This was the number of participants that did not miss more than 2 days of study medication over 28 days (less than 4 pills or 2 injections missed).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With a Patient Satisfaction Assessment</measure>
    <time_frame>On visit 4, which is 28 days (+/- 4 days) post-op/standard of care</time_frame>
    <description>Participants were monitored at the 28 (+/- 4) day post-op visit. This was measured through administering a participant satisfaction questionnaire ranging from strongly agree to strongly disagree.This is the number of participants that completed the questionnaire in response to agreeing it was difficult to remember to take the medication, agreeing that there was pain associated with the medication, and agreeing that the medication was easy to use.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Quality of Life From Baseline to 28 Days Post-op</measure>
    <time_frame>At baseline, and visit 4, which is 28 days (+/- 4 days) post-op/standard of care</time_frame>
    <description>This was measured through a validated health survey (SF-8™) provided by a healthcare company (Optum®), which measured overall physical and mental well-being, with responses ranging from none to very, not at all to extremely, etc. Change was calculated as the difference at baseline versus 28 days post op. The score was 0-100 and a higher score was considered a better outcome.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">400</enrollment>
  <condition>Gynecologic Cancer</condition>
  <condition>Venous Thromboembolism</condition>
  <arm_group>
    <arm_group_label>Oral apixaban</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Oral apixaban 2.5 mg tablet twice daily for 28 days post-surgery</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Subcutaneous enoxaparin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Subcutaneous enoxaparin 40mg once daily (QD) for 28 days post-surgery.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oral apixaban</intervention_name>
    <description>To evaluate the incidence of major bleeding (including CRNM bleeding) events in women undergoing surgery for gynecologic cancer with apixaban 2.5 mg BID compared to current standard of care, subcutaneous enoxaparin 40 mg QD for 28 days post surgery.</description>
    <arm_group_label>Oral apixaban</arm_group_label>
    <other_name>Eliquis</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Subcutaneous enoxaparin</intervention_name>
    <description>To evaluate the incidence of major bleeding (including CRNM bleeding) events in women undergoing surgery for gynecologic cancer with apixaban 2.5 mg BID compared to current standard of care, subcutaneous enoxaparin 40 mg QD for 28 days post surgery.</description>
    <arm_group_label>Subcutaneous enoxaparin</arm_group_label>
    <other_name>Lovenox</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Suitable candidate for surgery (meets appropriate performance status, no significant
             cardiac/renal/hepatic dysfunction

          -  Diagnosis of pelvic malignancy (suspected/confirmed ovarian, endometrial/uterine,
             cervical cancers, and vulvar cancers) undergoing surgical debulking,

          -  Women of childbearing potential (WOCBP) must have a negative serum or urine pregnancy
             test (minimum sensitivity 25 IU/L or equivalent units of HCG) within 24 hours prior to
             surgery,

          -  Women must not be breastfeeding, WOCBP must agree to follow instructions for method(s)
             of contraception for the duration of treatment with study drug(s) apixaban plus 5
             half-lives of study drug apixaban (2.5 days) plus 30 days (duration of ovulatory
             cycle) for a total of 32.5 days post-treatment completion.

        Exclusion Criteria:

          -  Malignancy or mass that is non-gynecologic in origin (mass/tumor of origin other than
             reproductive organ such as rectal, abdominal, breast)

          -  Positive pregnancy test on day of surgery,

          -  Known history of Venous (Thromboembolism) VTE prior to diagnosis (DVT or Pulmonary
             Embolism (PE)) due to increased underlying risk of new event

          -  Concomitant NSAIDS or other anticoagulant/antiplatelet therapy including
             Acetylsalicylic Acid (Aspirin) (ASA) &gt;81mg/day,

          -  Selective serotonin re uptake inhibitor (SSRIs) and Serotonin-nor-epinephrine re
             uptake inhibitor (SNRIs) (common anti-depressant therapies),

          -  Uncontrolled severe hypertension (systolic &gt;200 mmHg or diastolic &gt;120 mmHg),

          -  With prosthetic heart valves,

          -  Active bleeding condition (not limited to: thrombocytopenia, haemophilias, potential
             bleeding lesions, recent trauma or surgery, recent stroke, confirmed intracranial or
             intraspinal bleeding),

          -  Known or documented bleeding disorders not limited to: anti-phospholipid syndrome,
             homozygotes for Factor V Leiden deficiency, antithrombin III deficiency, protein C
             deficiency, Protein S deficiency, hyperhomocysteinemia, systemic lupus erythematous,
             or Prothrombin G2020 gene mutation,

          -  Significant renal disease as defined by creatinine clearance less than 30 mL/min,

          -  Significant liver disease as defined as Aspartate Transaminase (AST) or Alanine
             Transaminase (ALT) twice than normal,

          -  Concomitant use of dual strong inhibitors or inducers (CYP3A4, P-gp)

          -  Protein C deficiency (increased risk of skin necrosis do those on injectable
             anticoagulation),

          -  Documented allergy to apixaban and/or enoxaparin,

          -  Patient's deemed otherwise clinically unfit for clinical trial per Investigator's
             discretion
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>89 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Saketh Guntupalli, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Colorado, Denver</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Southern California Keck School of Medicine</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90089</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Colorado Denver</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>February 2, 2015</study_first_submitted>
  <study_first_submitted_qc>February 11, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 19, 2015</study_first_posted>
  <results_first_submitted>February 27, 2020</results_first_submitted>
  <results_first_submitted_qc>March 17, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">March 31, 2020</results_first_posted>
  <last_update_submitted>March 17, 2020</last_update_submitted>
  <last_update_submitted_qc>March 17, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 31, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Thromboembolism</mesh_term>
    <mesh_term>Venous Thromboembolism</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Enoxaparin</mesh_term>
    <mesh_term>Apixaban</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Informed Consent Form</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>Yes</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>January 30, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/71/NCT02366871/ICF_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>January 27, 2020</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/71/NCT02366871/Prot_SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Oral Apixaban</title>
          <description>Oral apixaban 2.5 mg tablet twice daily for 28 days post-surgery
Oral apixaban: To evaluate the incidence of major bleeding (including clinically relevant non-major (CRNM) bleeding) events in women undergoing surgery for gynecologic cancer with apixaban 2.5 mg twice a day (BID) compared to current standard of care, subcutaneous enoxaparin 40 mg QD for 28 days post surgery.</description>
        </group>
        <group group_id="P2">
          <title>Subcutaneous Enoxaparin</title>
          <description>Subcutaneous enoxaparin 40mg once daily (QD) for 28 days post-surgery.
Subcutaneous enoxaparin: To evaluate the incidence of major bleeding (including CRNM bleeding) events in women undergoing surgery for gynecologic cancer with apixaban 2.5 mg BID compared to current standard of care, subcutaneous enoxaparin 40 mg QD for 28 days post surgery.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="204"/>
                <participants group_id="P2" count="196"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="204"/>
                <participants group_id="P2" count="196"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Oral Apixaban</title>
          <description>Oral apixaban 2.5 mg tablet twice daily for 28 days post-surgery
Oral apixaban: To evaluate the incidence of major bleeding (including CRNM bleeding) events in women undergoing surgery for gynecologic cancer with apixaban 2.5 mg BID compared to current standard of care, subcutaneous enoxaparin 40 mg QD for 28 days post surgery.</description>
        </group>
        <group group_id="B2">
          <title>Subcutaneous Enoxaparin</title>
          <description>Subcutaneous enoxaparin 40mg once daily (QD) for 28 days post-surgery.
Subcutaneous enoxaparin: To evaluate the incidence of major bleeding (including CRNM bleeding) events in women undergoing surgery for gynecologic cancer with apixaban 2.5 mg BID compared to current standard of care, subcutaneous enoxaparin 40 mg QD for 28 days post surgery.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="204"/>
            <count group_id="B2" value="196"/>
            <count group_id="B3" value="400"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="58.0" lower_limit="21.0" upper_limit="87.0"/>
                    <measurement group_id="B2" value="58.5" lower_limit="18.0" upper_limit="89.0"/>
                    <measurement group_id="B3" value="58.0" lower_limit="18.0" upper_limit="89.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="204"/>
                    <measurement group_id="B2" value="196"/>
                    <measurement group_id="B3" value="400"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Race/ethnic group</title>
              <category_list>
                <category>
                  <title>White Non-Hispanic</title>
                  <measurement_list>
                    <measurement group_id="B1" value="158"/>
                    <measurement group_id="B2" value="164"/>
                    <measurement group_id="B3" value="322"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Hispanic</title>
                  <measurement_list>
                    <measurement group_id="B1" value="38"/>
                    <measurement group_id="B2" value="23"/>
                    <measurement group_id="B3" value="61"/>
                  </measurement_list>
                </category>
                <category>
                  <title>African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="11"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Surgical Intervention</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Open</title>
                  <measurement_list>
                    <measurement group_id="B1" value="165"/>
                    <measurement group_id="B2" value="152"/>
                    <measurement group_id="B3" value="317"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Minimally Invasive</title>
                  <measurement_list>
                    <measurement group_id="B1" value="39"/>
                    <measurement group_id="B2" value="44"/>
                    <measurement group_id="B3" value="83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Surgeries</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>total abdominal hysterectomy(TAH) with BSO/USO</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="116"/>
                    <measurement group_id="B2" value="112"/>
                    <measurement group_id="B3" value="228"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>total abdominal hysterectomy (w/out ovaries)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Bilateral/uni salpingo-oophorectomy(BSO)/USO</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="42"/>
                    <measurement group_id="B2" value="49"/>
                    <measurement group_id="B3" value="91"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Radical Hysterectomy</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                    <measurement group_id="B2" value="24"/>
                    <measurement group_id="B3" value="42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Lymph Node Dissection</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="93"/>
                    <measurement group_id="B2" value="88"/>
                    <measurement group_id="B3" value="181"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Bowel Resection</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="25"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Removal of Omentum</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="82"/>
                    <measurement group_id="B2" value="82"/>
                    <measurement group_id="B3" value="164"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Surgical Complication</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Length of Surgery</title>
          <units>minutes</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="204" lower_limit="31" upper_limit="600"/>
                    <measurement group_id="B2" value="215.5" lower_limit="17" upper_limit="743"/>
                    <measurement group_id="B3" value="209" lower_limit="17" upper_limit="743"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Confirm Origin</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Uterine Cancer</title>
                  <measurement_list>
                    <measurement group_id="B1" value="65"/>
                    <measurement group_id="B2" value="63"/>
                    <measurement group_id="B3" value="128"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Ovarian/Fallopian Cancer</title>
                  <measurement_list>
                    <measurement group_id="B1" value="77"/>
                    <measurement group_id="B2" value="64"/>
                    <measurement group_id="B3" value="141"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Cervical Cancer</title>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="18"/>
                    <measurement group_id="B3" value="30"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Vulva/Vaginal Cancer</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="13"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Other</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="11"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Benign</title>
                  <measurement_list>
                    <measurement group_id="B1" value="40"/>
                    <measurement group_id="B2" value="37"/>
                    <measurement group_id="B3" value="77"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Stage</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Low stage (I/II)</title>
                  <measurement_list>
                    <measurement group_id="B1" value="80"/>
                    <measurement group_id="B2" value="85"/>
                    <measurement group_id="B3" value="165"/>
                  </measurement_list>
                </category>
                <category>
                  <title>High stage (III/IV)</title>
                  <measurement_list>
                    <measurement group_id="B1" value="84"/>
                    <measurement group_id="B2" value="74"/>
                    <measurement group_id="B3" value="158"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Benign</title>
                  <measurement_list>
                    <measurement group_id="B1" value="40"/>
                    <measurement group_id="B2" value="37"/>
                    <measurement group_id="B3" value="77"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Body-mass index</title>
          <units>kg/m^2</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="27.4" lower_limit="11.0" upper_limit="50.5"/>
                    <measurement group_id="B2" value="26.5" lower_limit="15.8" upper_limit="57.2"/>
                    <measurement group_id="B3" value="27.0" lower_limit="11.0" upper_limit="57.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Incidence of Major Bleeding</title>
        <description>The International Society on Thrombosis and Hemostasis criteria (ISTH) will be used to assess incidence of major bleeding. Participants were monitored for up to 90 days. This is the number of participants who have had at least one major bleeding incidence during the time of observation.</description>
        <time_frame>Day 1 post-op/standard of care first medication dose to day 90 (+/-14 days) post-op/standard of care</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Oral Apixaban</title>
            <description>Oral apixaban 2.5 mg tablet twice daily for 28 days post-surgery
Oral apixaban: To evaluate the incidence of major bleeding (including CRNM bleeding) events in women undergoing surgery for gynecologic cancer with apixaban 2.5 mg BID compared to current standard of care, subcutaneous enoxaparin 40 mg QD for 28 days post surgery.</description>
          </group>
          <group group_id="O2">
            <title>Subcutaneous Enoxaparin</title>
            <description>Subcutaneous enoxaparin 40mg once daily (QD) for 28 days post-surgery.
Subcutaneous enoxaparin: To evaluate the incidence of major bleeding (including CRNM bleeding) events in women undergoing surgery for gynecologic cancer with apixaban 2.5 mg BID compared to current standard of care, subcutaneous enoxaparin 40 mg QD for 28 days post surgery.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Incidence of Major Bleeding</title>
          <description>The International Society on Thrombosis and Hemostasis criteria (ISTH) will be used to assess incidence of major bleeding. Participants were monitored for up to 90 days. This is the number of participants who have had at least one major bleeding incidence during the time of observation.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="204"/>
                <count group_id="O2" value="196"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Incidence of Clinically Relevant Non Major Bleeding Events</title>
        <description>Participants were monitored for up to 90 days. This is the number of participants with bleeding events that did not meet the ISTH criteria but still required intervention. This is the number of participants who had at least one non-major bleeding event during the time of observation.</description>
        <time_frame>Day 1 post-op/standard of care first dose of medication to day 90 (+/- 14 days) post-op/standard of care</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Oral Apixaban</title>
            <description>Oral apixaban 2.5 mg tablet twice daily for 28 days post-surgery
Oral apixaban: To evaluate the incidence of major bleeding (including CRNM bleeding) events in women undergoing surgery for gynecologic cancer with apixaban 2.5 mg BID compared to current standard of care, subcutaneous enoxaparin 40 mg QD for 28 days post surgery.</description>
          </group>
          <group group_id="O2">
            <title>Subcutaneous Enoxaparin</title>
            <description>Subcutaneous enoxaparin 40mg once daily (QD) for 28 days post-surgery.
Subcutaneous enoxaparin: To evaluate the incidence of major bleeding (including CRNM bleeding) events in women undergoing surgery for gynecologic cancer with apixaban 2.5 mg BID compared to current standard of care, subcutaneous enoxaparin 40 mg QD for 28 days post surgery.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Incidence of Clinically Relevant Non Major Bleeding Events</title>
          <description>Participants were monitored for up to 90 days. This is the number of participants with bleeding events that did not meet the ISTH criteria but still required intervention. This is the number of participants who had at least one non-major bleeding event during the time of observation.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="204"/>
                <count group_id="O2" value="196"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12"/>
                    <measurement group_id="O2" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Incidence of Venous Thromboembolism (VTEs): Deep Vein Thrombosis (DVT) or Pulmonary Embolism (PE)</title>
        <description>Participants were monitored for up to 90 days. Both DVTs and PEs will be measured using the Wells criteria, ultrasound, and/or CT. This is the number of participants who had at least one DVT or PE during the time of observation.</description>
        <time_frame>Day 1 post-op/standard of care to day first dose of medication 90 (+/- 14 days) post-op/standard of care</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Oral Apixaban</title>
            <description>Oral apixaban 2.5 mg tablet twice daily for 28 days post-surgery
Oral apixaban: To evaluate the incidence of major bleeding (including CRNM bleeding) events in women undergoing surgery for gynecologic cancer with apixaban 2.5 mg BID compared to current standard of care, subcutaneous enoxaparin 40 mg QD for 28 days post surgery.</description>
          </group>
          <group group_id="O2">
            <title>Subcutaneous Enoxaparin</title>
            <description>Subcutaneous enoxaparin 40mg once daily (QD) for 28 days post-surgery.
Subcutaneous enoxaparin: To evaluate the incidence of major bleeding (including CRNM bleeding) events in women undergoing surgery for gynecologic cancer with apixaban 2.5 mg BID compared to current standard of care, subcutaneous enoxaparin 40 mg QD for 28 days post surgery.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Incidence of Venous Thromboembolism (VTEs): Deep Vein Thrombosis (DVT) or Pulmonary Embolism (PE)</title>
          <description>Participants were monitored for up to 90 days. Both DVTs and PEs will be measured using the Wells criteria, ultrasound, and/or CT. This is the number of participants who had at least one DVT or PE during the time of observation.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="204"/>
                <count group_id="O2" value="196"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Who Met Medication Adherence Rates</title>
        <description>Participants were monitored for up to 28 days. This was measured through self-report, patient diaries, and the return of all medication bottles/syringes. This was the number of participants that did not miss more than 2 days of study medication over 28 days (less than 4 pills or 2 injections missed).</description>
        <time_frame>Day 1 post-op/standard of care first dose of medication to Day 28 (+/- 4 days) post-op/standard of care</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Oral Apixaban</title>
            <description>Oral apixaban 2.5 mg tablet twice daily for 28 days post-surgery
Oral apixaban: To evaluate the incidence of major bleeding (including CRNM bleeding) events in women undergoing surgery for gynecologic cancer with apixaban 2.5 mg BID compared to current standard of care, subcutaneous enoxaparin 40 mg QD for 28 days post surgery.</description>
          </group>
          <group group_id="O2">
            <title>Subcutaneous Enoxaparin</title>
            <description>Subcutaneous enoxaparin 40mg once daily (QD) for 28 days post-surgery.
Subcutaneous enoxaparin: To evaluate the incidence of major bleeding (including CRNM bleeding) events in women undergoing surgery for gynecologic cancer with apixaban 2.5 mg BID compared to current standard of care, subcutaneous enoxaparin 40 mg QD for 28 days post surgery.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Who Met Medication Adherence Rates</title>
          <description>Participants were monitored for up to 28 days. This was measured through self-report, patient diaries, and the return of all medication bottles/syringes. This was the number of participants that did not miss more than 2 days of study medication over 28 days (less than 4 pills or 2 injections missed).</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="204"/>
                <count group_id="O2" value="196"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="173"/>
                    <measurement group_id="O2" value="164"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With a Patient Satisfaction Assessment</title>
        <description>Participants were monitored at the 28 (+/- 4) day post-op visit. This was measured through administering a participant satisfaction questionnaire ranging from strongly agree to strongly disagree.This is the number of participants that completed the questionnaire in response to agreeing it was difficult to remember to take the medication, agreeing that there was pain associated with the medication, and agreeing that the medication was easy to use.</description>
        <time_frame>On visit 4, which is 28 days (+/- 4 days) post-op/standard of care</time_frame>
        <population>One patient did not answer the &quot;pain associated with taking the medication&quot; category.</population>
        <group_list>
          <group group_id="O1">
            <title>Oral Apixaban</title>
            <description>Oral apixaban 2.5 mg tablet twice daily for 28 days post-surgery
Oral apixaban: To evaluate the incidence of major bleeding (including CRNM bleeding) events in women undergoing surgery for gynecologic cancer with apixaban 2.5 mg BID compared to current standard of care, subcutaneous enoxaparin 40 mg QD for 28 days post surgery.</description>
          </group>
          <group group_id="O2">
            <title>Subcutaneous Enoxaparin</title>
            <description>Subcutaneous enoxaparin 40mg once daily (QD) for 28 days post-surgery.
Subcutaneous enoxaparin: To evaluate the incidence of major bleeding (including CRNM bleeding) events in women undergoing surgery for gynecologic cancer with apixaban 2.5 mg BID compared to current standard of care, subcutaneous enoxaparin 40 mg QD for 28 days post surgery.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With a Patient Satisfaction Assessment</title>
          <description>Participants were monitored at the 28 (+/- 4) day post-op visit. This was measured through administering a participant satisfaction questionnaire ranging from strongly agree to strongly disagree.This is the number of participants that completed the questionnaire in response to agreeing it was difficult to remember to take the medication, agreeing that there was pain associated with the medication, and agreeing that the medication was easy to use.</description>
          <population>One patient did not answer the &quot;pain associated with taking the medication&quot; category.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="188"/>
                <count group_id="O2" value="187"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Difficult remembering to take medication</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="188"/>
                    <count group_id="O2" value="187"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Agree</title>
                  <measurement_list>
                    <measurement group_id="O1" value="23"/>
                    <measurement group_id="O2" value="23"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Neutral</title>
                  <measurement_list>
                    <measurement group_id="O1" value="16"/>
                    <measurement group_id="O2" value="15"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Disagree</title>
                  <measurement_list>
                    <measurement group_id="O1" value="149"/>
                    <measurement group_id="O2" value="149"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pain associated with taking the medication</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="187"/>
                    <count group_id="O2" value="187"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Agree</title>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="92"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Neutral</title>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                    <measurement group_id="O2" value="25"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Disagree</title>
                  <measurement_list>
                    <measurement group_id="O1" value="173"/>
                    <measurement group_id="O2" value="70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Was medication easy to take</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="188"/>
                    <count group_id="O2" value="187"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Agree</title>
                  <measurement_list>
                    <measurement group_id="O1" value="186"/>
                    <measurement group_id="O2" value="110"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Neutral</title>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="21"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Disagree</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Quality of Life From Baseline to 28 Days Post-op</title>
        <description>This was measured through a validated health survey (SF-8™) provided by a healthcare company (Optum®), which measured overall physical and mental well-being, with responses ranging from none to very, not at all to extremely, etc. Change was calculated as the difference at baseline versus 28 days post op. The score was 0-100 and a higher score was considered a better outcome.</description>
        <time_frame>At baseline, and visit 4, which is 28 days (+/- 4 days) post-op/standard of care</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Oral Apixaban</title>
            <description>Oral apixaban 2.5 mg tablet twice daily for 28 days post-surgery
Oral apixaban: To evaluate the incidence of major bleeding (including CRNM bleeding) events in women undergoing surgery for gynecologic cancer with apixaban 2.5 mg BID compared to current standard of care, subcutaneous enoxaparin 40 mg QD for 28 days post surgery.</description>
          </group>
          <group group_id="O2">
            <title>Subcutaneous Enoxaparin</title>
            <description>Subcutaneous enoxaparin 40mg once daily (QD) for 28 days post-surgery.
Subcutaneous enoxaparin: To evaluate the incidence of major bleeding (including CRNM bleeding) events in women undergoing surgery for gynecologic cancer with apixaban 2.5 mg BID compared to current standard of care, subcutaneous enoxaparin 40 mg QD for 28 days post surgery.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Quality of Life From Baseline to 28 Days Post-op</title>
          <description>This was measured through a validated health survey (SF-8™) provided by a healthcare company (Optum®), which measured overall physical and mental well-being, with responses ranging from none to very, not at all to extremely, etc. Change was calculated as the difference at baseline versus 28 days post op. The score was 0-100 and a higher score was considered a better outcome.</description>
          <units>score on a scale</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="204"/>
                <count group_id="O2" value="196"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>physical score-baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="50.7" lower_limit="19.2" upper_limit="64.5"/>
                    <measurement group_id="O2" value="49.7" lower_limit="16.2" upper_limit="62.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>physical score-visit 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="39.2" lower_limit="21.0" upper_limit="58.6"/>
                    <measurement group_id="O2" value="38.5" lower_limit="17.8" upper_limit="60.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Physical change</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5.9" lower_limit="-35.4" upper_limit="30.5"/>
                    <measurement group_id="O2" value="-6.2" lower_limit="-36.1" upper_limit="28.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>mental score-baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="50.7" lower_limit="19.2" upper_limit="64.5"/>
                    <measurement group_id="O2" value="49.7" lower_limit="16.2" upper_limit="62.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>mental score-visit 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="50.7" lower_limit="18.5" upper_limit="69.4"/>
                    <measurement group_id="O2" value="49.3" lower_limit="19.7" upper_limit="62.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mental change</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.8" lower_limit="-30.3" upper_limit="30.8"/>
                    <measurement group_id="O2" value="0.0" lower_limit="-30.7" upper_limit="41.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>90 (+/- 14) days post first study medication dose</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Oral Apixaban</title>
          <description>Oral apixaban 2.5 mg tablet twice daily for 28 days post-surgery
Oral apixaban: To evaluate the incidence of major bleeding (including CRNM bleeding) events in women undergoing surgery for gynecologic cancer with apixaban 2.5 mg BID compared to current standard of care, subcutaneous enoxaparin 40 mg QD for 28 days post surgery.</description>
        </group>
        <group group_id="E2">
          <title>Subcutaneous Enoxaparin</title>
          <description>Subcutaneous enoxaparin 40mg once daily (QD) for 28 days post-surgery.
Subcutaneous enoxaparin: To evaluate the incidence of major bleeding (including CRNM bleeding) events in women undergoing surgery for gynecologic cancer with apixaban 2.5 mg BID compared to current standard of care, subcutaneous enoxaparin 40 mg QD for 28 days post surgery.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>CTCAE (4.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="196"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="196"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Admitted for abdominal pain and emesis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="196"/>
              </event>
              <event>
                <sub_title>Admitted for clostridium difficile</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="196"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Admitted for neutropenic fever from chemotherapy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="196"/>
              </event>
              <event>
                <sub_title>Admitted for pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="196"/>
              </event>
              <event>
                <sub_title>Admitted for excess kidney fluid and stent placement</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="196"/>
              </event>
              <event>
                <sub_title>Admitted for Nausea/emesis from chemotherapy</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="196"/>
              </event>
              <event>
                <sub_title>Admitted for dehydration</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="196"/>
              </event>
              <event>
                <sub_title>Admitted for small bowel obstruction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="196"/>
              </event>
              <event>
                <sub_title>Admitted for pelvic infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="196"/>
              </event>
              <event>
                <sub_title>Admitted for wound closure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="196"/>
              </event>
              <event>
                <sub_title>Admitted for nausea and stomach flu</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="196"/>
              </event>
              <event>
                <sub_title>Admitted for ongoing UTI/sepsis - resolved</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="196"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Admitted for ileus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="196"/>
              </event>
              <event>
                <sub_title>Admitted for wound Infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="196"/>
              </event>
              <event>
                <sub_title>Admitted for vaginal cuff bleeding from open vessel from surgery stitches</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="196"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>CTCAE (4.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="53" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="45" subjects_at_risk="196"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Hematoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="196"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="196"/>
              </event>
              <event>
                <sub_title>Suspected allergic reaction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="196"/>
              </event>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="196"/>
              </event>
              <event>
                <sub_title>Bruising</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="196"/>
              </event>
              <event>
                <sub_title>Skin rash/cellulitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="196"/>
              </event>
              <event>
                <sub_title>Vaginal spotting/discharge/bleeding</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="196"/>
              </event>
              <event>
                <sub_title>Epistaxis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="196"/>
              </event>
              <event>
                <sub_title>Abscess/discharge from incision</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="196"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="196"/>
              </event>
              <event>
                <sub_title>Hospitalized in 28 days</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="196"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Wound infection</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="204"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="196"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Saketh Guntupalli</name_or_title>
      <organization>University of Colorado, Anschutz Medical Campus</organization>
      <phone>303-724-2033</phone>
      <email>saketh.guntupalli@cuanschutz.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

